Urology News and Research

Latest Urology News and Research

PSA test is still the best option for diagnosing prostate cancer

When it comes to the documented 40 percent effectiveness of PSA testing in preventing death from prostate cancer, neither the American Cancer Society nor the discoverer of the PSA protein, Richard Ablin, are telling the public the complete story.

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Watson Pharmaceuticals resolves Actos patent litigation

Watson Pharmaceuticals, Inc, today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.

11 Mar 2010

Patients who undergo gastric bypass surgery increase their risk of developing kidney stones

Patients who undergo gastric bypass surgery experience changes in their urine composition that increase their risk of developing kidney stones, research from UT Southwestern Medical Center investigators suggests.

10 Mar 2010

Adult female stress urinary incontinence: Uroplasty launches new endoscopic injection needle

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the introduction of a newly designed endoscopic injection needle that can be used in conjunction with the system used to inject Macroplastique®. Macroplastique is a soft-tissue urethral bulking agent used to treat adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. This permanent, nonresorbable material is injected into the tissues surrounding the urethra to help improve urethral closure to enhance bladder control.

10 Mar 2010

Bioniche Pharma introduces Mefoxin in frozen premix bags

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.

9 Mar 2010

Watson Laboratories sued over ANDA filing for generic Opana ER

Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.

9 Mar 2010

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Gen-Probe's PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology's (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco.

8 Mar 2010

Postoperative complications more likely to occur at low-volume institutions

The frequency of post-operative complications following surgery for liver cancer is associated with a hospital having a low volume of liver surgery. Investigators at The Cancer Institute of New Jersey (CINJ) are presenting that finding at the 63rd Annual Society of Surgical Oncology Symposium taking place this week in St. Louis. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Predictive Biosciences today announced that the Company will be presenting its novel Multi-Analyte Diagnostic Readout approach to the development of a non-invasive, urinary biomarker based assay for the detection of bladder cancer during the 2010 Genitourinary Cancers Symposium, being held March 5-7 in San Francisco.

5 Mar 2010

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society National Board of Directors and director of the University of Alabama at Birmingham Comprehensive Cancer Center.

5 Mar 2010

Paralyzed Veterans: Much more needs to be done for America's veterans with disabilities

Today, Paralyzed Veterans of America National President Gene A. Crayton praised Congressional leaders for making Department of Veterans Affairs healthcare funding an advance appropriation, but urged that much more needs to be done for our nation's veterans with disabilities.

5 Mar 2010

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

Urinary catheterization of men and women: NAFC releases new consumer educational resource

The National Association For Continence (NAFC) has released a new consumer educational resource, focusing on catheterization procedures and care in the United States. The Urinary Catheterization of Men and Women pamphlet is the newest addition to NAFC's library of educational materials available to consumers seeking knowledge of management and treatment options for medical problems related to incontinence. It is also helpful as an educational supplement to nurses giving instructions to patients regarding their self-care.

4 Mar 2010

Macroplastique effective for stress urinary incontinence in women

Uroplasty, Inc. highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the April 2010 print edition of The Journal of Urology(R). The 24-month study evaluated the durability of Macroplastique for stress urinary incontinence in women with previously documented success at 12 months. Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant improvement from their 12-month assessment. Additionally, 67% of the patients implanted with Macroplastique were dry at the 24-month follow-up visit.

4 Mar 2010

Urology News and Research

Latest Urology News and Research

PSA test is still the best option for diagnosing prostate cancer

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Watson Pharmaceuticals resolves Actos patent litigation

Patients who undergo gastric bypass surgery increase their risk of developing kidney stones

Adult female stress urinary incontinence: Uroplasty launches new endoscopic injection needle

Bioniche Pharma introduces Mefoxin in frozen premix bags

Watson Laboratories sued over ANDA filing for generic Opana ER

Necessity of repeat biopsy in suspected prostate cancer: Gen-Probe's PROGENSA PCA3 assay can help determine

Postoperative complications more likely to occur at low-volume institutions

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Predictive Biosciences to present its novel MADR approach during 2010 GU Symposium

Men should discuss risks, benefits with doctor before undergoing prostate-cancer screening

Paralyzed Veterans: Much more needs to be done for America's veterans with disabilities

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Urinary catheterization of men and women: NAFC releases new consumer educational resource

Macroplastique effective for stress urinary incontinence in women

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Urology News and Research

Latest Urology News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in